Label Changes for:

Edurant (Rilpivirine) Tablets

December 2012

Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

December 2012

 

WARNINNGS AND PRECAUTIONS

  • Depressive Disorders: The adverse reaction depressive disorders (depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation) has been reported with Edurant…
  • Hepatotoxicity: Hepatic adverse events have been reported in patients receiving a Rilpivirine containing regimen.,,

 

August 2012

 

WARNINGS AND PRECAUTIONS

Immune Reconstitution Syndrome
Hide
(web2)